cookie

Translate

martedì 4 luglio 2017

It's Official: Mexico's President Signs a Bill Legalizing Medical Marijuana

The North American marijuana industry is on fire, and marijuana stock investors have clearly taken notice. A majority of pot stocks with a market cap north of $200 million have seen triple-digit percentage returns over the trailing 12 months.
Cannabis research firm ArcView projects that legal North American weed sales (recreational and medical) will catapult from $6.9 billion in 2016 to more than $22 billion by 2021. With an estimated $46.4 billion in sales conducted on the black market last year in North America, the opportunity for businesses to move consumers toward legal channels appears to offer a sustainable growth trend.
Image source: Getty Images.
Yet, expansion isn't a given. Despite a record number of Americans wanting to see both recreational and medical pot legalized, the U.S. federal government has dug in its heels on any efforts to reschedule marijuana. Concern over minors gaining access to marijuana, an inability to measure to what extent drivers who've used cannabis are impaired, and insufficient benefit-versus-risk profiles from clinical studies, has halted the U.S. government from loosening laws governing the industry.

Marijuana stock investors rejoice: Mexico legalizes medical cannabis

However, marijuana stock investors do have something to cheer about if they look south of the border.
On June 19, Mexican President Enrique Pena Nieto signed a bill into law that makes medical marijuana legal in the country. The bill that found its way to Pena Nieto's desk had been overwhelmingly approved by Mexico's Congress nearly two months ago. Pena Nieto had previously opposed legalizing weed, but changed his tune in recent years.
Mexico's medical weed bill will now classify cannabis as a "therapeutic" drug, and the government will now lean on Mexico's Ministry of Health to draft and implement regulations controlling medical cannabis use, including tetrahydrocannabinol (THC), the psychoactive component of cannabis. The Ministry of Health will also be responsible for developing and overseeing a research program to study pot's impact on patients before considering an expansion of the program to cover broader use.
Image source: Getty Images.
Mexico's push to legalize is particularly exciting news for Medical Marijuana, Inc.(NASDAQOTH: MJNA), the very first publicly listed marijuana stock. Medical Marijuana, Inc. is mostly an investment company, with its holdings in clinical-stage cannabinoid-based drug developer Axim Biotechnologies making up a good chunk of its current valuation. But it also fully owns HempMeds Mexico, which imports and distributes cannabidiol (CBD)-based hemp oil products to medical patients.  Not only was it the first company to be given the green light to import CBD products into Mexico, but last week's legislation appears to open the door for an increase in future sales.
There's also hope from Canada's quartet of larger medical cannabis producers and retailers -- Canopy Growth Corp. (NASDAQOTH: TWMJF)MedReleaf (TSX: LEAF)Aphria (NASDAQOTH: APHQF), and Aurora Cannabis (NASDAQOTH: ACBFF) -- that Mexico's actions could provide an impetus to push a Canadian recreational marijuana bill over its current hurdles. Public opinion toward marijuana improves annually, which is potentially good news for these four providers, all of which are expanding their grow capacity either organically or through acquisitions. Canada legalized medical cannabis all the way back in 2001.

Mexico's legalization still presents challenges

Yet, in spite of Mexico's legalization of medical cannabis, challenges still remain within the industry. For instance, Mexico has long had an issue with drug cartels, which could make selling legal pot a challenge. Enforcing regulations on the legal industry could be difficult when there's such a rampant amount of black market activity.
The pushback in Mexico against medical marijuana is also arguably higher than it is in the United States. A Quinnipiac University poll in the U.S. found that 93% of respondents wants to see medical weed legal. However, the Catholic Church in Mexico widely opposes the use of marijuana, and a Nov. 2015 telephone poll by the El Universal newspaper found that 66% of Mexicans opposed legalizing the drug (albeit the question appears to have been phrased in terms of recreational legalization as opposed to medical). Comparatively, support for recreational legalization in the U.S. tends to hover around 60%. In other words, Mexico's legalization of medical weed seems to be more of a baby step than a full-ranging expansion of medical pot access.
Image source: Getty Images.
What's more, it doesn't appear as if the U.S. will be following the suggestion of Pena Nieto and aligning its marijuana policies with that of its neighbor to the south. The U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule marijuana last year away from its current schedule I categorization following two petitions to do so, but chose to keep its status the same. The DEA cited a lack of risk-versus-benefit analyses, as well as a lack of marijuana-use oversight as reasons to keep its scheduling unchanged. Congress shares the same opinion, with lawmakers wanting to see additional clinical evidence before considering a federal medical marijuana bill.
Mexico's legislation also fails to clear up how it'll deal with keeping children from accessing marijuana, as well as keeping impaired drivers off the roads. The Health Ministry may be able to outline a plan after a bit of trial and error, but it could take years to hash out (no pun intended). That's not good news for marijuana stocks that are aiming for broader use.
Though Mexico's actions do represent a baby step forward for the pot industry, it's not yet a sufficient enough reason for investors to place their hard-earned money and faith in marijuana stocks.
10 stocks we like better than Medical Marijuana, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medical Marijuana, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

It's Official: Mexico's President Signs a Bill Legalizing Medical Marijuana

martedì 27 giugno 2017

Colorado County Gives High School Graduates $420K in Cannabis-Funded Scholarships

Colorado’s cannabis industry has now helped give $420,000 in scholarships to 210 Pueblo County high school graduates. On June 20, the high school seniors each received $2,000 in cannabis tax-funded grants from the Pueblo County Scholarship Fund and the Colorado Opportunity Scholarship Initiative.
Pueblo County Commissioner Sal Pace told the Pueblo Chieftan that the dollar amount was a mere coincidence, not a reference to ’420’ cannabis slang. In February, estimates put the projected amount at $425,000.
The program is believed to be the first academic scholarship in the world to be funded by cannabis tax.
County officials on Tuesday threw an event in front of the Pueblo County Courthouse to recognize the scholarship recipients. Of the 210 recipients, 143 were in attendance to receive certificates and recognition in front of a crowd of about 300 people.
Jeanette Garcia, a member of the Colorado Commission for Higher Education, told the Chieftain that she was extremely proud of the students.
“Congratulations to our scholarship recipients, especially to the city and county of Pueblo for having the vision to invest in our own citizens,” she said.
All graduating high school students from the county are automatically eligible for the scholarship, provided they attend either Pueblo Community College or Colorado State University-Pueblo, the latter of which recently established an Institute of Cannabis Research.
Last year, when the program began, 23 students received scholarships.
“Last year was a pilot, and we started it early because we had the COSI funds available that we weren’t expecting,” Pace told the Chieftan. “This year was the first full-blown year of the scholarship program.”
Beverly Duran, executive director of the Pueblo Hispanic Education Foundation, said that every student who applied and met the qualifications received a scholarship.
To meet a few of the students who received scholarships from the program, check out the story from the Chieftain here.


Colorado County Gives High School Graduates $420K in Cannabis-Funded Scholarships

sabato 24 giugno 2017

ITALIA - Legalizzazione cannabis. Direzione Nazionale Antimafia conferma nella sua relazione al Parlamento

"Sembra coerente l'adozione di una rigorosa e chiara politica di legalizzazione della vendita della cannabis, accompagnata da una parallela azione a livello internazionale, e, in particolare europeo, che consenta la creazione, in prospettiva, di una più ampia aerea in cui il fenomeno sia regolato in modo omogeno". E' quanto si legge nella Relazione annuale della Direzione nazionale antimafia, presentata ieri mattina al Senato dal procuratore Nazionale antimafia e antiterrorismo, Franco Roberti. Una prospettiva "favorevole alla legalizzazione prendendo atto sulla base di numeri, fatti, indagini e processi in nostro possesso - si sottolinea nella Relazione - del fallimento delle politiche proibizioniste". "Questo Ufficio, conferma, - prosegue ancora la Dna - anche alla luce delle nuove questioni esaminate e dei nuovi dati pervenuti, la necessità di concentrare le risorse dello Stato finalizzate alla repressione dei reati su fenomeni più gravi ed allarmanti del traffico di droghe leggere". Il mercato degli stupefacenti - continua la relazione - mentre in alcuni settori è sostanzialmente stabile (eroina e cocaina) in altri è in significativa ascesa (droghe sintetiche e cannabis) con la conseguenza che rimangono confermate (se non accresciute) le stime sul complessivo giro di affari del narcotraffico sia a livello globale che a livello nazionale. Che, infatti, a livello globale superano i 560 miliardi di euro e che, in Italia, è di circa 30 miliardi di euro (pari a circa il 2% del PIL nazionale). "Numeri dimostrativi dell'enorme rilievo macro-economico del narcotraffico che - secondo la Dna - confermano che la partita del contrasto al narcotraffico rimane decisiva".

ITALIA - Legalizzazione cannabis. Direzione Nazionale Antimafia conferma nella sua relazione al Parlamento

lunedì 5 giugno 2017

Facciamo cadere il governo!

Se si va a votare a Settembre, non si può discutere alla camere la legge sulla cannabis.
Ora la cannabis è diventata la criptonite dei governi di sinistra. Eh si. Se con Letta, si era fatta cancellare la finigiovanardi, il prezzo è stato fare cadere il governo.

Renzi è riuscito a scamparla. E' ancora in sella al governo, pur non essendone parte. Solo in Italia riescono queste sfacciate imposizioni di potere. E così non si vuole portare avanti la legge sulla cannabis, perchè tanto non può essere approvata. Ma i governi si alternano e questo tema viene attentamente evitato.

E' il complotto della cannabis. Riuscire a riunire nuove persone che non si oppongano alla legalizzazione, ma li blocchino, li devino, attirino l'attenzione di persone dallo stesso lato, evadendo e lasciando che, dallo stesso lato, si utilizzi la peggiore delle qualità italiane; il Tafazzismo.

Il Tafazzismo è quella arte tutta italiana di martellarsi i coglioni esibendo la propria ignoranza.

E così non si parlerà di cannabis.




venerdì 2 giugno 2017

ITALIA - Legalizzazione cannabis. Lo stato dell'arte della legge: on.Giachetti

"Se si vota a settembre è impensabile approvare una legge del genere prima, abbiamo visto il tempo che c'è voluto per le Unioni civili o il testamento biologico. Detto questo, non posso che condividere il tentativo di Della Vedova anch'io credo sia giusto che su questa proposta, trasversale ma sostenuta da un numero consistente di parlamentari dem, si esprima il Parlamento, in aula o in commissione. Anche perché, come abbiamo già visto altre volte, il Paese è più avanti della sua classe dirigente. Lo dicono i sondaggi, e figure che di solito vengono ascoltate nella lotta alla mafia, vedi il procuratore della Dna Franco Roberti secondo cui è fallimentare la sproporzione tra forze impiegate per perseguire il consumo di cannabis e i risultati ottenuti. Sarebbe utile che la politica si interrogasse su questo. Anche perché questa non è una proposta di governo, né di partito. Quello che auspico è un dibattito che lasci liberi di parlamentari, ci sono tutte le condizioni per fare un passo avanti. Se non sarà così ne prenderemo atto. E comunque la prima volta che una proposta di legge del genere arriva alla discussione in aula, questo ha già un significato politico rilevante". Così, in una intervista all'Unità, Roberto Giachetti, vicepresidente Pd della Camera, primo firmatario della proposta di legge per la legalizzazione della cannabis. E aggiunge: "Un dibattito farebbe comunque maturare la politica, dopo anni in cui è scappata davanti ad alcuni temi, con giochetti e rimpalli tra le due camere. Discutiamo, poi ognuno agirà secondo convinzione, come sempre su temi sensibili e trasversali". Perché legalizzare? "Due le ragioni per me fondamentali. La prima come dicono tutti gli esperti è un modo concreto per sottrarre alla criminalità organizzata una fetta consistente di introiti. Partendo dal presupposto che oggi le droghe leggere sono di fatto libere, si trovano facilmente: il fenomeno è concreto e diffuso, noi vogliamo gestirlo. La seconda ragione è che oggi, a differenza di un tempo, anche le droghe leggere vengono tagliate con sostanze chimiche pericolosissime. Dunque, visto che si continua a comprare e fumare canne, preferisco che lo si faccia con sostanze controllate. Fermo restando che gli studi riconoscono che la cannabis produce meno danni, anche in termini di incidenti, di alcol e tabacco. Poi c'è tutto il tema dell'uso medico della cannabis, non solo per la terapia del dolore. Così vorrei sottrarre il dibattito a una discussione sterilmente ideologica nessuno di noi è 'a favore' delle droghe".

ITALIA - Legalizzazione cannabis. Lo stato dell'arte della legge: on.Giachetti

lunedì 29 maggio 2017

Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

IRVINE, CA--(Marketwired - May 26, 2017) - Cannabis Science, Inc. (OTC PINKCBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts. As the world's largest customer, the U.S. Federal Government issues over $192 billion in contracts and over $450 billion in grants annually.
Cannabis Science has completed its registration in the U.S. Government's System for Award Management (SAM), and has applied for and received a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency's CAGE Program Office at the U.S. Department of Defense. Cannabis Science is now listed with all U.S. companies eligible for Federal Government Contracts. "Achieving eligibility to access contracting opportunities with the U.S. Federal Government is a significant step for Cannabis Science," stated Mr. Raymond C. Dabney, Cannabis Science's President, CEO, and Co-founder. "I believe we can leverage the unique experience and expertise of our company to win new business and grow Cannabis Science's revenue base. We also plan to work closely with our strategic partners and collaborators to access Federal contracting and grant opportunities."
Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:
§ 541711 - Research and Development In Biotechnology
§ 621511 - Medical Laboratories
§ 624230 - Emergency and Other Relief Services
SAM is the primary vendor database for the U.S. Federal Government. Having vendor information immediately available allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, research & development projects, and particular supply needs, as well as for pandemic alert and other emergency requirements.
Cannabis Science intends to explore funding opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others.
As part of its mandate to study drug abuse and addiction and other health effects of both legal and illegal drugs, NIDA funds a wide range of research on marijuana (cannabis); its main psychotropic ingredient, delta-9-tetrahydrocannabinol (THC); and chemicals related to THC (cannabinoids). Research suggests that THC and other cannabinoids may have potential in the treatment of pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions. NIDA has provided and continues to provide funding for research related to therapeutic uses of cannabinoids as it pertains to its mission, including studies on the use of THC and cannabidiol (CBD), another chemical constituent of marijuana, for the treatment of pain (as an alternative to opioid pain relievers), addiction, and other disorders. Research on therapeutic uses of marijuana or of specific chemicals in the marijuana plant for other diseases and conditions is supported by other components of NIH as is appropriate to their mission. For a complete listing of all projects funded by NIH examining the potential therapeutic benefits of cannabinoids, see the Therapeutic Cannabinoid Research category in the NIH Report database.
The vast majority of research proposals received and funded by NIH on therapeutic benefits of cannabinoids have examined individual cannabinoid chemicals or, in a few cases, marijuana leaves delivered through some means other than smoking. Research proposals submitted to any NIH Institute of Center (IC) to study therapeutic benefits of marijuana or one of its ingredients must meet the same accepted standards of scientific design as any other proposal and, on the basis of peer review, should meet public health significance and IC priorities to be competitive with other applications that qualify for funding. NIDA is a scientific, not a policy-making agency. The same is true for the NIH as a whole. NIDA's role is to conduct and support scientific research on drugs and drug abuse and to advise the public and policy-makers, such as Congress, the White House Office of the National Drug Control Policy, and the U.S. Drug Enforcement Administration on the results of that research -- with the goal of ensuring that the nation's drug policies are informed by science. That said, NIDA does closely watch legislative changes both nationally and at the state level and supports research that studies how changing drug policies -- for instance laws around recreational or therapeutic use of marijuana -- affect rates of substance use and related public health issues.
About Cannabis Science, Inc. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts